From the helm: Immutep's (ASX:IMM) Executive Director & CEO Marc Voigt
Update: 2022-04-05
Description
In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep's (ASX:IMM) Executive Director and CEO, Marc Voigt.
Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.
In this video Marc discusses:
- (0:40 ) What IMM does and its key strength in the market
- (1:27 ) The impact of the FDA's recent feedback on its lead product
- (2:53 ) IMM's collaborations with big pharma names like Pfizer & Merck
- (4:03 ) When to expect data from its current clinical trials
- (5:10 ) What's coming up for IMM
Note: This interview was filmed on 22 March 2022.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
